Cargando…

Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions

Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder that is characterized by neurodegeneration, cognitive impairment, and an eventual inability to perform daily tasks. The etiology of Alzheimer’s is complex, with numerous environmental and genetic factors contributing to the diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Seto, Mabel, Weiner, Rebecca L., Dumitrescu, Logan, Hohman, Timothy J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086309/
https://www.ncbi.nlm.nih.gov/pubmed/33926499
http://dx.doi.org/10.1186/s13024-021-00452-5
_version_ 1783686497146241024
author Seto, Mabel
Weiner, Rebecca L.
Dumitrescu, Logan
Hohman, Timothy J.
author_facet Seto, Mabel
Weiner, Rebecca L.
Dumitrescu, Logan
Hohman, Timothy J.
author_sort Seto, Mabel
collection PubMed
description Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder that is characterized by neurodegeneration, cognitive impairment, and an eventual inability to perform daily tasks. The etiology of Alzheimer’s is complex, with numerous environmental and genetic factors contributing to the disease. Late-onset AD is highly heritable (60 to 80%), and over 40 risk loci for AD have been identified via large genome-wide association studies, most of which are common variants with small effect sizes. Although these discoveries have provided novel insight on biological contributors to AD, disease-modifying treatments remain elusive. Recently, the concepts of resistance to pathology and resilience against the downstream consequences of pathology have been of particular interest in the Alzheimer’s field as studies continue to identify individuals who evade the pathology of the disease even into late life and individuals who have all of the neuropathological features of AD but evade downstream neurodegeneration and cognitive impairment. It has been hypothesized that a shift in focus from Alzheimer’s risk to resilience presents an opportunity to uncover novel biological mechanisms of AD and to identify promising therapeutic targets for the disease. This review will highlight a selection of genes and variants that have been reported to confer protection from AD within the literature and will also discuss evidence for the biological underpinnings behind their protective effect with a focus on genes involved in lipid metabolism, cellular trafficking, endosomal and lysosomal function, synaptic function, and inflammation. Finally, we offer some recommendations in areas where the field can rapidly advance towards precision interventions that leverage the ideas of protection and resilience for the development of novel therapeutic strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13024-021-00452-5.
format Online
Article
Text
id pubmed-8086309
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80863092021-04-30 Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions Seto, Mabel Weiner, Rebecca L. Dumitrescu, Logan Hohman, Timothy J. Mol Neurodegener Review Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder that is characterized by neurodegeneration, cognitive impairment, and an eventual inability to perform daily tasks. The etiology of Alzheimer’s is complex, with numerous environmental and genetic factors contributing to the disease. Late-onset AD is highly heritable (60 to 80%), and over 40 risk loci for AD have been identified via large genome-wide association studies, most of which are common variants with small effect sizes. Although these discoveries have provided novel insight on biological contributors to AD, disease-modifying treatments remain elusive. Recently, the concepts of resistance to pathology and resilience against the downstream consequences of pathology have been of particular interest in the Alzheimer’s field as studies continue to identify individuals who evade the pathology of the disease even into late life and individuals who have all of the neuropathological features of AD but evade downstream neurodegeneration and cognitive impairment. It has been hypothesized that a shift in focus from Alzheimer’s risk to resilience presents an opportunity to uncover novel biological mechanisms of AD and to identify promising therapeutic targets for the disease. This review will highlight a selection of genes and variants that have been reported to confer protection from AD within the literature and will also discuss evidence for the biological underpinnings behind their protective effect with a focus on genes involved in lipid metabolism, cellular trafficking, endosomal and lysosomal function, synaptic function, and inflammation. Finally, we offer some recommendations in areas where the field can rapidly advance towards precision interventions that leverage the ideas of protection and resilience for the development of novel therapeutic strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13024-021-00452-5. BioMed Central 2021-04-29 /pmc/articles/PMC8086309/ /pubmed/33926499 http://dx.doi.org/10.1186/s13024-021-00452-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Seto, Mabel
Weiner, Rebecca L.
Dumitrescu, Logan
Hohman, Timothy J.
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
title Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
title_full Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
title_fullStr Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
title_full_unstemmed Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
title_short Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
title_sort protective genes and pathways in alzheimer’s disease: moving towards precision interventions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086309/
https://www.ncbi.nlm.nih.gov/pubmed/33926499
http://dx.doi.org/10.1186/s13024-021-00452-5
work_keys_str_mv AT setomabel protectivegenesandpathwaysinalzheimersdiseasemovingtowardsprecisioninterventions
AT weinerrebeccal protectivegenesandpathwaysinalzheimersdiseasemovingtowardsprecisioninterventions
AT dumitresculogan protectivegenesandpathwaysinalzheimersdiseasemovingtowardsprecisioninterventions
AT hohmantimothyj protectivegenesandpathwaysinalzheimersdiseasemovingtowardsprecisioninterventions